'Stay awake' pill may boost brain function: Study

Image
IANS London
Last Updated : Aug 29 2015 | 2:13 PM IST

A drug that is used to help people with sleep disorders stay awake can boost cognitive functions in healthy people, a new study says.

Researchers reviewed 24 studies on the drug modafinil, carried out between 1990 and 2015, and found that it appeared to improve cognitive function, RT.com reported.

Some of the studies also showed gains in flexible thinking, increasing ability to combine information or cope with novelty. The drug didn't seem to influence creativity either way.

However, researchers found that improvement wasn't seen every time, on every test, or for every person. They also found that the studies failed to show any enhancement in the areas of attention, learning and memory.

"What emerged was that the longer and the more complex the task ... the more consistently modafinil showed cognitive benefits," said study co-author Anna-Katharine Brem from Oxford University was reported as saying.

Modafinil, like Adderall and Ritalin, is increasingly being used by college students and adults who don't suffer from ADHD or sleep disorders, but are searching for greater productivity.

The drugs work by increasing the brain's level of dopamine and norepinephrine to boost concentration and alertness.

The drugs can have negative health consequences, though, especially at large doses.

Researchers also found that many of the cognitive tests used in the studies were more appropriate for people with neuropsychiatric illness or neurological disorders.

"The problem with this is that healthy people perform very well in them without taking the drug and so improvements in performance on a substance are harder, if not impossible, to detect," Brem observed.

Researchers said that the studies only gave participants the drug once, so long term claims are hard to make.

Still, they said the benefits of the drug for enhancing attention, executive functions, learning, and memory appear much stronger.

The study was published in the journal European Neuropsychopharmacology.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 29 2015 | 2:02 PM IST

Next Story